Glaxosmithkline Share News (GSK)

UPDATE 1-Decision on Ebola mass vaccination in August at earliest - WHO

* Will depend on results of trials, epidemic's course * Guinea, Liberia, Sierra Leone to conduct phase III trials * WHO says know vaccines safe (adds details, background) By Stephanie Nebehay GENEVA, Feb 27 (Reuters) - An independent advisory body will decide in August a

Decision on widespread Ebola vaccination in August at earliest - WHO

GENEVA, Feb 27 (Reuters) - An independent advisory body will decide in August at the earliest on whether to recommend widespread introduction of Ebola vaccine, depending on results of clinical trials and the epidemic's course, the World Health Organization said on Friday. Reporting on a thr

UPDATE 2-GSK's new chairman Hampton to take charge in May

* RBS chairman Hampton takes reins at GSK on May 7 * Move follows appointment of Davies to lead RBS * GSK facing tough times; CEO's 2014 bonus cut by 51 pct (Adds detail on CEO's reduced bonus, paragraph 5) By Ben Hirschler LONDON, Feb 26 (Reuters) - GlaxoSmithKline said

GSK's new chairman Hampton to take charge in May

LONDON, Feb 26 (Reuters) - GlaxoSmithKline said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, marking an earlier transition than initially anticipated. Hampton, who chairs Royal Bank of Scotland, was named as the pharmace

GlaxoSmithKline Confirms Hampton As Incoming Chairman

UPDATE: RBS Ends Standalone Global Investment Bank Amid Group Losses

RBS Posts Loss After Citizens Writedown But Hails Underlying Progress

Howard Davies set to be confirmed as RBS chairman -sources

By Alexander Smith and Lauren Tara LaCapra LONDON/NEW YORK, Feb 25 (Reuters) - Royal Bank of Scotland Group PLC is set to confirm the appointment of Howard Davies as its new chairman on Thursday, a source familiar with the matter told Reuters. Davies, a former top UK regulator who ser

GSK set to complete $20 bln Novartis asset swap next week

LONDON, Feb 25 (Reuters) - GlaxoSmithKline said on Wednesday it expected to conclude a $20 billion-plus three-part asset swap with Novartis in the week commencing March 2, following progress in obtaining clearances for the deal. GSK is forming a consumer health joint venture with Novartis,

GSK will complete Novartis three-way deal by end of next week

UK drugs giant GlaxoSmithKline says it has made "good progress" on regulatory and legal issues towards completion of its deal with Swiss rival Novartis. GSK said it expected to complete the deal next week, just under a year after it was first announced, with the two pharmaceuticals groups trading ov

UPDATE 1-Medicago wins contract to develop Ebola treatments

(Adds details on background, competition) Feb 24 (Reuters) - Canadian drugmaker Medicago said it received a contract from a U.S. federal agency to develop three different potential treatments for Ebola. The company said on Tuesday it would make the antibodies in its Quebec facility fo

UPDATE 1-Novartis AG wins approval to buy GSK cancer drugs, with conditions

(Adds Canada approving deal, details on divestitures, background on three-way deal) WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday. Canada's competit

Canada competition bureau approves GlaxoSmithKline/Novartis deal

OTTAWA, Feb 23 (Reuters) - Canada's Competition Bureau on Monday approved a deal between GlaxoSmithKline PLC and Novartis AG, noting in a statement that U.S. authorities had already said the transaction could go ahead. The companies agreed last April to the transaction that includes GSK buy

CORRECTED-Novartis AG wins approval to buy GSK cancer drugs with conditions

(Corrects name of inhibitor in paragraph two to MEK from MIK) WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs with conditions, the Federal Trade Commission said on Monday. To win approval for the $16 billion deal, Nov

Australian regulator says will not oppose GSK, Novartis deals

SYDNEY, Feb 20 (Reuters) - Australia's competition regulator said on Friday it will not oppose a three part deal between Novartis and GlaxoSmithKline to trade more than $20 billion worth of assets, following approval from EU regulators. The companies agreed last April to the transaction tha